(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Ключови думи
Резюме
Описание
Sepsis is the leading cause of acute kidney injury (AKI) and a major cause of death. Patients with SA-AKI have a high mortality and morbidity and are at risk of developing chronic kidney disease. AP is a homodimeric endogenous enzyme present in many cells and organs, e.g., intestines, placenta, liver, bone, kidney, and granulocytes. It exerts detoxifying effects through dephosphorylation of endotoxins; pathogen associated molecular pattern molecules (PAMPS e.g., lipopolysaccharide and damage-associated molecular pattern molecules (DAMPS e.g., adenosine tri- and di-phosphate). In animal models of sepsis and AKI, administration of AP attenuates the inflammatory response, improves renal function and/or reduces mortality.
AM-Pharma B.V. is developing AP as a novel, recombinant chimeric human AP medicinal product, called recAP, to be used as an intravenous infusion for the treatment of SA-AKI. In the Phase 2 trial STOP-AKI, a survival benefit was observed in the two highest dose groups, 0.8 mg/kg and 1.6 mg/kg groups, compared to the placebo group. There were no safety or tolerability concerns for any of the doses tested (0.4, 0.8 and 1.6 mg/kg). The 1.6 mg/kg recAP dose was selected for this Phase 3 trial based on the significant survival benefit observed. PK/PD simulations also confirmed this dose to have the most pronounced treatment effect.
The primary objective of this Phase 3 trial is to confirm the mortality benefit seen in STOP-AKI by demonstrating a reduction in 28 day all cause mortality in patients with SA-AKI treated with 1.6 mg/kg recAP.
Дати
Последна проверка: | 04/30/2020 |
Първо изпратено: | 05/27/2020 |
Очаквано записване подадено: | 05/27/2020 |
Първо публикувано: | 06/01/2020 |
Изпратена последна актуализация: | 05/27/2020 |
Последна актуализация публикувана: | 06/01/2020 |
Действителна начална дата на проучването: | 10/14/2020 |
Приблизителна дата на първично завършване: | 08/14/2023 |
Очаквана дата на завършване на проучването: | 02/14/2024 |
Състояние или заболяване
Интервенция / лечение
Biological: active
Other: placebo
Фаза
Групи за ръце
Arm | Интервенция / лечение |
---|---|
Experimental: active recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions | Biological: active patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP. |
Placebo Comparator: placebo matching placebo | Other: placebo Placebo |
Критерии за допустимост
Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
Полове, допустими за проучване | All |
Приема здрави доброволци | Да |
Критерии | Inclusion Criteria: 1. 18 years or older. 2. In the ICU or intermediate care unit for clinical reasons. 3. Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.: 1. suspected or proven bacterial or viral infection. and 2. on vasopressor therapy (≥0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy. The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score. 4. Have AKI according to at least one of the below KDIGO criteria, a to d: 1. An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours. or 2. A relative increase in CR to ≥1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days. or 3. A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation. or 4. If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days. 5. Provision of signed and dated ICF in accordance with local regulations. Exclusion Criteria: 1. Documented CKD as specified below: 1. At selected sites where enrolment of 'moderate' CKD patients is allowed: 'Severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2. - For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥25 mL/min/1.73 m2. - For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD. 2. At all other sites: 'Moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2. - For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥45 mL/min/1.73 m2. - For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD. 2. Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C). 3. Acute pancreatitis with no established source of infection. 4. Urosepsis related to suspected or proven urinary tract obstruction. 5. Main cause of AKI not sepsis. 6. Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population. 7. Severe burns requiring ICU treatment. 8. Severely immunosuppressed, e.g. due to: - hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease - solid organ transplantation - leukopenia not related to sepsis, i.e., preceding sepsis - Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) - receiving chemotherapy within 30 days prior to Screening. 9. At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless. 10. Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion). 11. Previous administration of recAP. 12. Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC). 13. Current or planned extracorporeal membrane oxygenation (ECMO). 14. On RRT >24 hours before start of trial drug. 15. No longer on vasopressor therapy at time of randomization. 16. On continuous vasopressor therapy for >72 hours before start of trial drug. 17. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. 18. Not feasible to start trial drug within: 1. 48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy. or 2. 24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy. 19. Pregnant or nursing women. |
Резултат
Първични изходни мерки
1. 28-day all-cause mortality [28 days]
Вторични изходни мерки
1. To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE). [90 Days]
2. To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes. [28 days]
3. To investigate the effect of recAP on length of stay (LOS) in ICU. [28 days]
4. To investigate the effect of recAP on 90-day allcause mortality [90 days]